R

Roche

Global pharmaceuticals and diagnostics company

Programs & Solutions Manager - Corporate & Commercial Services

Full-TimeUpdated Deadline 11/10/26
No salary listed
Senior
Bachelor's
Madrid, Spain+1 moreMore locations: Warsaw, Poland
In Person
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • Hold a university degree in Business, Life Sciences, or a related field.
  • Have at least 5 years of procurement experience, with category experience in commercial marketing and/or corporate services such as external workforce or consulting.
  • Have a proven record of leading supplier innovation, complex cost-out initiatives, or high-value negotiations.
  • Manage cross-functional strategic programs using structured methodologies while designing and deploying market- or supplier-driven solutions.
  • Use data and insights to identify opportunities, quantify business impact, structure trade-offs, and track program performance.
  • Demonstrate the ability to enter new category spaces and complex business problem statements, using transferable procurement capabilities and structured thinking to establish clarity and momentum.
  • Demonstrate the ability to challenge standard procurement metrics, prioritize speed-to-impact, and scale or repurpose proven frameworks.
  • Present effectively and navigate senior-level discussions, influence decisions, and translate complex market opportunities into compelling business cases.
  • Connect the Roche procurement network and broader business using technical expertise and commercial acumen.
  • Be fluent in English to a business level.
Responsibilities
  • Deliver complex strategic programs and projects, contributing to or owning workstreams in large-scale procurement initiatives such as cost transformations, complex negotiations, and sourcing strategy for senior stakeholders.
  • Co-create and deliver digital and/or service-based market- and supplier-driven solutions that address customer needs and business challenges, leveraging external market innovation and expertise to create tangible value.
  • Identify, clarify, and diagnose complex business customer problem statements with Commercial and Corporate leaders and Global Procurement colleagues, seeking non-traditional avenues to accelerate value realization.
  • Manage and execute a portfolio of solutions and projects that realize multifaceted value beyond traditional procurement metrics in a dynamic global environment.
  • Apply, refine, and champion solution frameworks, tools, and execution approaches for beyond-procurement innovation models and complex strategic programs.
  • Advise and influence business stakeholders to align strategic direction and co-create solutions using market insights, storytelling, and data-driven recommendations.
  • Build and nurture Global Procurement and Roche-wide cross-functional networks, fostering collaboration, psychological safety, and shared best practices.
Desired Qualifications
  • Management consulting experience is ideal.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 28th, 2026
Roche launches BAP1 test to distinguish mesothelioma from other cancers

Roche has launched the VENTANA BAP1 (SP527) test worldwide to help diagnose mesothelioma, a rare and deadly cancer. The automated immunohistochemistry assay helps pathologists tell mesothelioma apart from other cancers, including non-small cell lung cancer, and from benign tissue growth. The test is registered as a Class I IVD with the US Food and Drug Administration and has IVDR approval as a Class C device. Roche announced the launch in Basel on October 28, 2026. Most patients are diagnosed late, with median overall survival of just 12 to 18 months. BAP1 works alongside the recently launched MTAP and Claudin-4 tests, which help preserve limited tissue samples for molecular sequencing. "Timely differential diagnosis of mesothelioma is critical to help deliver the best outcome for patients," said Matt Sause, chief executive officer of Roche Diagnostics.

Yahoo Finance
Oct 27th, 2026
Zymeworks signs Roche deal worth up to $718M in milestones, shows 65% response in ovarian cancer

Zymeworks has agreed a collaboration with Roche on ZW209, a T-cell engager that targets DLL3-positive tumours, including small cell lung cancer. The deal is subject to Hart-Scott-Rodino Act clearance. Zymeworks would receive $55 million upfront and $40 million when a Phase 1b study begins. It could also earn up to $718 million in milestones, plus tiered royalties from high single digits to mid-teens. Roche would fund research and development, and take over later development and commercialisation. Zymeworks will run the first global trial. Zymeworks also reported updated data for ZW191 in platinum-resistant ovarian cancer. In high-grade serous disease, confirmed response rates were 65% at 6.4 mg/kg and 55% at 9.6 mg/kg. The company is seeking partners to fund further development.

Yahoo Finance
Oct 27th, 2026
Roche wins CE Mark for compact cobas smart e immunoanalyser with 100+ planned assays

Roche has received the CE Mark for its cobas smart e immunoanalyser, a compact testing platform for smaller hospitals and laboratories. The company announced the approval in Basel on October 27, 2026. The device fits in a footprint of under one square metre and has a planned menu of over 100 assays. Reaction times are 18 minutes or less for more than 90% of Roche immunoassays, which can help local facilities cut turnaround times. It uses the same reagents and Elecsys technology as Roche's high-throughput systems, so results stay consistent across sites. Roche says it needs one minute of daily operator input and cuts hands-on maintenance by up to two-thirds compared with earlier platforms. It joins the cobas e 402 and cobas e 801 units, completing a range for clinics through to large hospital laboratories.

Yahoo Finance
Oct 26th, 2026
Zymeworks licenses ZW209 to Roche in deal worth up to $813M, with $55M upfront

Zymeworks has granted Roche exclusive worldwide rights to develop and commercialise ZW209, a DLL3-targeting trispecific T-cell engager. The deal brings $55.0 million upfront, up to $758.0 million in further milestones, and tiered royalties. Roche will take on most later development and commercialisation work. That fits Zymeworks' partnership-heavy, capital-light model, though future cash from ZW209 now depends largely on Roche meeting its own targets. The company also reported Phase 1 data for ZW191, an ovarian cancer antibody-drug conjugate. It showed activity across folate receptor alpha expression levels and a more favourable tolerability profile at 6.4mg/kg.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.